培美曲塞联合顺铂用于非小细胞肺癌术前新辅助化疗的效果和耐受性

Comparative Study of Alimta Plus Cisplatin as Preoperative Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer

目的观察培美曲塞(pemetrexed,Alimta)联合顺铂(DDP)用于Ⅲ期非小细胞肺癌(NSCLC)术前新辅助化疗的效果及耐受性。方法62例Ⅲ期NSCLC手术患者,术前接受新辅助化疗。其中,培美曲塞组28例,接受Alimta+DDP方案,与同期接受诺维苯(NVB)+DDP方案(NP组)34例作比较。结果培美曲塞组CR 2例,PR 13例,总有效率53.6%;NP组CR 3例,PR 13例,总有效率47.1%,两组有效率比较差异无统计学意义(P>0.05)。化疗后肿瘤分期下降两组分别为:培美曲塞组46.4%(13/28),NP组35.3%(12/34),两组比较差异无统计学意义(P>0.05)。结论培美曲塞联合DDP用于NSCLC术前新辅助化疗效果肯定,该方案可作为NSCLC术前新辅助化疗的可选择方案。

Objective To evaluate efficacy and toxicity of Alimta plus cisplatin（DDP） regimen in preoperative adjuvant chemotherapy in patients with m stages NSCLC. Methods In all of the 62 patients with stage Ⅲ NSCLC,28 cases received Alimta ＋ DDP regimen, while the other 34 cases received NVB ＋ DDP（NP） regimen. The therapeutic efficacy and toxicity of Alimta ＋ DDP regimen were observed and with NP regimen. Results The overall response rate was 53.6% of Alimta group with 2 complete response（CR） and 13 partial response（ PR）, and 47.1% in the NP group with 3 CR and 13 PR （P 〉 0.05）. There were 13 （46.4%） , down after preoperative chemotherapy in Alimta group, and 12 （35.3%）in NP group（P 〉 0.05）. The main toxicity was myelosuppression, there was no significant difference between the two groups（ P 〉 0.05 ）. Conclusion Alimta ＋ DDP regimen was a highly active regimen of the neoadjuvant chemotherapy for NSCLC, and it could be used as a regimen for the preoperative neoadjuvant chemotherapy of NSCLC.